Skip to main content

Advertisement

SpringerLink
Log in

Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review

  • Published:
Pituitary Aims and scope Submit manuscript

Abstract

Long-acting somatostatin analogs (SSA) are widely used for the treatment of acromegaly achieving biochemical control of the disease in 50–75% of the patients. One of the goals of the treatment of acromegaly is the control of tumor growth, especially in patients in whom SSAs are used as first-line therapy. Over the recent years, there has been growing evidence that SSAs are able to induce tumor shrinkage in patients with acromegaly. However, most of the data are from patients under treatment with octreotide, either subcutaneously or intramuscularly with long-acting formulation, whereas the data on lanreotide SR or Autogel are very few. Indeed, octreotide and lanreotide, i.e. the two commercially available SSAs, show slight differences in pharmacokinetics and patterns of receptor affinities with potentially different therapeutic effects. We aimed to perform a systematic review of literature data concerning the shrinkage effects of long-acting lanreotide in patients with acromegaly. The analysis was focused on the following issues: differences in shrinkage effects between primary and secondary medical treatment, predictive value of baseline tumor volume and correlation between biochemical control and shrinkage effects. The peer-reviewed medical literature was searched to identify clinical trials studying the effects of lanreotide SR or Autogel on adenoma size in acromegaly. To be included in this analysis, studies had one of the following designs: randomized controlled trial; prospective, nonrandomized trial; retrospective study. Twenty-two studies were found to be eligible for the final analysis, in which tumor size was measured as an end-point for lanreotide treatment. Overall a total of 32.8% of patients experienced a variable degree (from 10 to 77%) of tumor shrinkage during lanreotide SR or Autogel treatment. The analysis showed that tumor shrinkage was more frequent in naïve patients as compared with those previously treated by radiotherapy, surgery or drugs other than lanreotide. The data on the correlation between tumor shrinkage and baseline tumor size were discordant, but when baseline tumor size was specified, more than 80% of patients undergoing shrinkage under lanreotide Autogel had macroadenomas. Finally, with lanreotide Autogel there was no evident correlation between biochemical response and tumor shrinkage. Our systematic review of the literature shows that lanreotide particularly when used as first-line therapy is able to quite frequently induce tumor shrinkage in patients with acromegaly. This finding suggests that this drug may have a role in the primary treatment of acromegaly.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Melmed S (2006) Medical progress: acromegaly. N Engl J Med 355:2558–2573. doi:10.1056/NEJMra062453

    Article  CAS  PubMed  Google Scholar 

  2. Freda PU, Katznelson L, van der Lely AJ et al (2005) Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 90:4465–4473. doi:10.1210/jc.2005-0260

    Article  CAS  PubMed  Google Scholar 

  3. Giustina A, Barkan A, Casanueva FF et al (2000) Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85:526–529. doi:10.1210/jc.85.2.526

    Article  CAS  PubMed  Google Scholar 

  4. Melmed S, Casanueva FF, Cavagnini F et al (2002) Guidelines for acromegaly management. J Clin Endocrinol Metab 87:4054–4058. doi:10.1210/jc.2002-011841

    Article  CAS  PubMed  Google Scholar 

  5. Bevan JS (2005) The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 90:1856–1863. doi:10.1210/jc.2004-1093

    Article  CAS  PubMed  Google Scholar 

  6. Melmed S, Sterneberg R, Cook D et al (2005) A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 90(7):4405–4410. doi:10.1210/jc.2004-2466

    Article  CAS  PubMed  Google Scholar 

  7. Melmed S, Casanueva F, Cavagnini F et al (2005) Consensus statement: medical management of acromegaly. Eur J Endocrinol 153:737–740. doi:10.1530/eje.1.02036

    Article  CAS  PubMed  Google Scholar 

  8. Newman CB, Melmed S, George A et al (1998) Octreotide as primary treatment for acromegaly. J Clin Endocrinol Metab 83:3034–3040. doi:10.1210/jc.83.9.3034

    Article  CAS  PubMed  Google Scholar 

  9. Gola M, Bonadonna S, Mazziotti G et al (2006) Resistance to somatostatin analogs in acromegaly: an evolving concept? J Endocrinol Invest 29:86–93

    CAS  PubMed  Google Scholar 

  10. Colao A, Martino E, Cappabianca P et al (2006) First-line therapy of acromegaly: a statement of the A.L.I.C.E. (acromegaly primary medical treatment learning and improvement with continuous medical education) Study Group. J Endocrinol Invest 29:1017–1020

    CAS  PubMed  Google Scholar 

  11. Amato G, Mazziotti G, Rotondi M et al (2002) Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf) 56:65–71. doi:10.1046/j.0300-0664.2001.01438.x

    Article  CAS  Google Scholar 

  12. Casarini AP, Pinto EM, Jallad RS et al (2006) Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3. J Endocrinol Invest 29:826–830

    CAS  PubMed  Google Scholar 

  13. Resmini E, Dadati P, Ravetti JL et al (2007) Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient. J Clin Endocrinol Metab 92:1592–1599. doi:10.1210/jc.2006-2084

    Article  CAS  PubMed  Google Scholar 

  14. Giustina A, Zaltieri G, Negrini F, Wehrenberg WB (1996) The pharmacological aspects of the treatment of acromegaly. Pharmacol Res 34:247–268. doi:10.1006/phrs.1996.0095

    Article  CAS  PubMed  Google Scholar 

  15. Murray RD, Melmed S (2008) A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab 93:2957–2968

    Article  CAS  PubMed  Google Scholar 

  16. Coy DH, Taylor JE (1996) Receptor-specific somatostatin analogs: correlations with biological activity. Metabolism 45(8, Suppl 1):21–23. doi:10.1016/S0026-0495(96)90073-6

    Article  CAS  PubMed  Google Scholar 

  17. Astruc B, Marbach P, Bouterfa H et al (2005) Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. J Clin Pharmacol 45:836–844. doi:10.1177/0091270005277936

    Article  CAS  PubMed  Google Scholar 

  18. Morange I, De Boisvilliers F, Chanson P et al (1994) Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. J Clin Endocrinol Metab 79:145–151. doi:10.1210/jc.79.1.145

    Article  CAS  PubMed  Google Scholar 

  19. Marek J, Hána V, Krsek M et al (1994) Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide. Eur J Endocrinol 131:20–26. doi:10.1530/eje.0.1310020

    Article  CAS  PubMed  Google Scholar 

  20. Caron P, Cogne M, Gusthiot-Joudet B et al (1995) Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201-995). Eur J Endocrinol 132:320–325. doi:10.1530/eje.0.1320320

    Article  CAS  PubMed  Google Scholar 

  21. Caron P, Morange-Ramos I, Cogne M, Jaquet P (1997) Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab 82:18–22. doi:10.1210/jc.82.1.18

    Article  CAS  PubMed  Google Scholar 

  22. Giusti M, Ciccarelli E, Dallabonzana D et al (1997) Clinical results of long-term slow-release lanreotide treatment of acromegaly. Eur J Clin Invest 27:277–284. doi:10.1046/j.1365-2362.1997.1190659.x

    Article  CAS  PubMed  Google Scholar 

  23. Colao A, Marzullo P, Ferone D et al (1999) Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly. J Endocrinol Invest 22:40–47

    CAS  PubMed  Google Scholar 

  24. Suliman M, Jenkins R, Ross R et al (1999) Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide. J Endocrinol Invest 22:409–418

    CAS  PubMed  Google Scholar 

  25. Verhelst JA, Pedroncelli AM, Abs R et al (2000) Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients. Eur J Endocrinol 143:577–584. doi:10.1530/eje.0.1430577

    Article  CAS  PubMed  Google Scholar 

  26. Cannavò S, Squadrito S, Curtò L et al (2000) Results of a two-year treatment with slow release lanreotide in acromegaly. Horm Metab Res 32:224–229. doi:10.1055/s-2007-978625

    Article  PubMed  Google Scholar 

  27. Baldelli R, Colao A, Razzore P et al (2000) Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg). J Clin Endocrinol Metab 85:4099–4103. doi:10.1210/jc.85.11.4099

    Article  CAS  PubMed  Google Scholar 

  28. Cozzi R, Barausse M, Sberna M et al (2000) Lanreotide 60 mg, a longer-acting somatostatin analog: tumor shrinkage and hormonal normalization in acromegaly. Pituitary 3:231–238. doi:10.1023/A:1012832230598

    Article  CAS  PubMed  Google Scholar 

  29. Cannavò S, Squadrito S, Curtò L et al (2001) Effectiveness of slow-release lanreotide in previously operated and untreated patients with GH-secreting pituitary macroadenoma. Horm Metab Res 33:618–624. doi:10.1055/s-2001-17910

    Article  PubMed  Google Scholar 

  30. Attanasio R, Barausse M, Cozzi R (2001) GH/IGF-I normalization and tumor shrinkage during long-term treatment of acromegaly by lanreotide. J Endocrinol Invest 24:209–216

    CAS  PubMed  Google Scholar 

  31. Attanasio R, Baldelli R, Pivonello R et al (2003) Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. J Clin Endocrinol Metab 88:5258–5265. doi:10.1210/jc.2003-030266

    Article  CAS  PubMed  Google Scholar 

  32. Lucas T, Astorga R, Catalá M, Spanish Multicentre Lanreotide Study Group on Acromegaly (2003) Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage. Clin Endocrinol (Oxf) 58:471–481. doi:10.1046/j.1365-2265.2003.01741.x

    Article  CAS  Google Scholar 

  33. van Thiel SW, Romijn JA, Biermasz NR et al (2004) Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. Eur J Endocrinol 150:489–495. doi:10.1530/eje.0.1500489

    Article  PubMed  Google Scholar 

  34. Alexopoulou O, Abrams P, Verhelst J et al (2004) Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol 151:317–324. doi:10.1530/eje.0.1510317

    Article  CAS  PubMed  Google Scholar 

  35. Maiza JC, Vezzosi D, Matta M et al (2007) Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol (Oxf) 67:282–289. doi:10.1111/j.1365-2265.2007.02878.x

    Article  CAS  Google Scholar 

  36. Karavitaki N, Turner HE, Adams CB et al (2008) Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide. Clin Endocrinol (Oxf) 68:970–975. doi:10.1111/j.1365-2265.2007.03139.x

    Article  CAS  Google Scholar 

  37. Attanasio R, Lanzi R, Losa M et al (2008) Effects of lanreotide Autogel on growth hormone, insulin-like growth factor 1, and tumor size in acromegaly: a 1-year prospective multicenter study. Endocr Pract 14:846–855

    PubMed  Google Scholar 

  38. Colao A, Auriemma RS, Rebora A et al (2008) Significant tumor shrinkage after lanreotide autogel-120 mg as first-line treatment of acromegaly. Clin Endocrinol (Oxf) (Dec):15 Epub ahead of print

  39. Sharma K, Patel YC, Srikant CB (1996) Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol 10:1688–1696. doi:10.1210/me.10.12.1688

    Article  CAS  PubMed  Google Scholar 

  40. Danila DC, Haidar JN, Zhang X et al (2001) Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors. J Clin Endocrinol Metab 86:2976–2981. doi:10.1210/jc.86.7.2976

    Article  CAS  PubMed  Google Scholar 

  41. Naidich MJ, Russell EJ (1999) Current approaches to imaging of the sellar region and pituitary. Endocrinol Metab Clin North Am 28:45–79. doi:10.1016/S0889-8529(05)70057-8

    Article  CAS  PubMed  Google Scholar 

  42. Barkan AL, Lloyd RV, Chandler WF et al (1988) Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201–995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab 67:1040–1048

    Article  CAS  PubMed  Google Scholar 

  43. Colao A, Pivonello R, Auriemma RS et al (2006) Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab 91:2112–2118. doi:10.1210/jc.2005-2110

    Article  CAS  PubMed  Google Scholar 

  44. Molitch ME (2003) Dopamine resistance of prolactinomas. Pituitary 6:19–27. doi:10.1023/A:1026225625897

    Article  CAS  PubMed  Google Scholar 

  45. Maison P, Tropeano AI, Macquin-Mavier I, Giustina A, Chanson P (2007) Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. J Clin Endocrinol Metab 9:1743–1747. doi:10.1210/jc.2006-2547

    Article  Google Scholar 

  46. De Marinis L, Bianchi A, Mazziotti G et al (2008) The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly. Pituitary 11:13–20. doi:10.1007/s11102-007-0062-6

    Article  CAS  PubMed  Google Scholar 

  47. Giustina A, Mazziotti G, Canalis E (2008) Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 29:535–559. doi:10.1210/er.2007-0036

    Article  CAS  PubMed  Google Scholar 

  48. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ (1996) Octreotide. N Engl J Med 334:246–254. doi:10.1056/NEJM199601253340408

    Article  CAS  PubMed  Google Scholar 

  49. Giustina A, Veldhuis JD (1998) Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 19:717–797. doi:10.1210/er.19.6.717

    Article  CAS  PubMed  Google Scholar 

  50. Florio T, Thellung S, Corsaro A et al (2003) Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro. Clin Endocrinol (Oxf) 59:115–128. doi:10.1046/j.1365-2265.2003.01811.x

    Article  CAS  Google Scholar 

  51. Dasgupta P (2004) Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol Ther 102:61–85. doi:10.1016/j.pharmthera.2004.02.002

    Article  CAS  PubMed  Google Scholar 

  52. Bronstein M, Musolino N, Jallad R et al (2005) Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days. Clin Endocrinol (Oxf) 63:514–519. doi:10.1111/j.1365-2265.2005.02372.x

    Article  CAS  Google Scholar 

  53. Caron P, Beckers A, Cullen DR et al (2002) Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab 87:99–104. doi:10.1210/jc.87.1.99

    Article  CAS  PubMed  Google Scholar 

  54. Ashwell SG, Bevan JS, Edwards OM et al (2004) The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR. Eur J Endocrinol 150:473–480. doi:10.1530/eje.0.1500473

    Article  CAS  PubMed  Google Scholar 

  55. Caron P, Bex M, Cullen DR et al (2004) One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel. Clin Endocrinol (Oxf) 60:734–740. doi:10.1111/j.1365-2265.2004.02045.x

    Article  CAS  Google Scholar 

  56. Caron P, Cogne M, Raingeard I, Bex-Bachellerie V, Kuhn JM (2006) Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly. Clin Endocrinol (Oxf) 64:209–214. doi:10.1111/j.1365-2265.2006.02450.x

    Article  CAS  Google Scholar 

  57. Lucas T, Astorga R, Spanish-Portuguese Multicentre Autogel Study Group on Acromegaly (2006) Efficacy of lanreotide Autogel administered every 4–8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial. Clin Endocrinol (Oxf) 65:320–326. doi:10.1111/j.1365-2265.2006.02595.x

    Article  CAS  Google Scholar 

  58. Abrams P, Alexopoulou O, Abs R, Maiter D, Verhelst J (2007) Optimalization and cost management of lanreotide-Autogel therapy in acromegaly. Eur J Endocrinol 157:571–577. doi:10.1530/EJE-07-0366

    Article  CAS  PubMed  Google Scholar 

  59. Ronchi CL, Boschetti M, Degli Uberti EC et al (2007) Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. Clin Endocrinol (Oxf) 67:512–519

    CAS  Google Scholar 

  60. Bevan JS, Newell-Price J, Wass JA et al (2008) Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective. Clin Endocrinol (Oxf) 68:343–349

    CAS  Google Scholar 

  61. Andries M, Glintborg D, Kvistborg A, Hagen C, Andersen M (2008) A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly. Clin Endocrinol (Oxf) 68:473–480

    CAS  Google Scholar 

Download references

Conflict of interest statement

G.M. has nothing to declare. A.G. is consultant for Ipsen, Italfarmaco, Novartis and Pfizer, and has received lecture fees from Ipsen, Italfarmaco and Pfizer.

Author information

Authors and Affiliations

  1. Department of Medical and Surgical Sciences, University of Brescia, c/o Endocrinology Service, Montichiari Hospital, Via Ciotti 154, 25018, Montichiari, Italy

    Gherardo Mazziotti & Andrea Giustina

Authors
  1. Gherardo Mazziotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrea Giustina
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrea Giustina.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mazziotti, G., Giustina, A. Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review. Pituitary 13, 60–67 (2010). https://doi.org/10.1007/s11102-009-0169-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11102-009-0169-z

Keywords

Search

Navigation